CALIXAR will participate to the 7th AMR Conference at Basel (Switzerland) on March 16 - 17, 2023

March 3, 2023

CALIXAR is a French biotechnology company with expertise in the identification and isolation of functional membrane-based therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Those stable and functional therapeutic targets will be available in a ready-to-discovery format within the next few years.

Vincent CORVEST, Senior Scientist, is pleased to join the 2023 AMR Conference to exchange on CALIXAR’s skills that will be a key point in the development of novel antimicrobial treatments.

Meet Vincent during the 2-day event and give yourself the chance to achieve your discovery projects.

About the AMR Conference:

The #AMRconference is a platform for SMEs, start-ups, big pharma, academia, investors, and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.

The “AMR Conference” was started in 2017 to offer a platform for meeting experts from business, science, clinics, finance, regulatory affairs, and intellectual property.  This year, this event is supported by the BEAM Alliance which is a network of European biotech and diagnostics companies.

For more information and meet us: AMR Conference

Share this post

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.